Physician
Malla, Yogesh
Malla, Yogesh was paid $380K by Medicaid between Jan 2018 and Oct 2024, across 16 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 33% of everything it billed.
33Billing provider infoMALLA, YOGESH
PADUCAH, KY 42003
PADUCAH, KY 42003
33aNPI1205817525assigned 11/14/2005
33bProvider typeInterventional Pain Medicine Physician
28Total paid$380K
24GClaims12,621
24DCodes billed16
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Kentucky
Rank by total paid#9 of 24
Median peer was paid$58K
This provider vs. median6.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,341 | $54K | |
| 2019 | 2,586 | $65K | |
| 2020 | 2,765 | $79K | |
| 2021 | 2,085 | $77K | |
| 2022 | 1,294 | $48K | |
| 2023 | 998 | $35K | |
| 2024incomplete | 552 | $23K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 33% | 2,737 | 2,436 | $126K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 2,897 | 2,583 | $100K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 2,269 | 2,013 | $44K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7.7% | 510 | 386 | $29K |
| 62323 | 6.3% | 713 | 697 | $24K | |
| 64493 | 4.4% | 361 | 360 | $17K | |
| 64494 | 2.6% | 361 | 360 | $10K | |
| 64483 | 2.3% | 112 | 110 | $9K | |
| 62321 | 1.9% | 194 | 193 | $7K | |
| 99442 | <1% | 210 | 208 | $4K | |
| 64484 | <1% | 52 | 52 | $4K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 212 | 205 | $3K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.